Overview
Lobbying Costs
1,875,000€
Financial year: Jan 2015 - Dec 2015
Lobbyists (Full time equivalent)
5.25 Fte (13)
Lobbyists with EP accreditation
0
High-level Commission meetings
0
Lobbying Costs over the years
-
Info
Novartis Pharma
EU Transparency Register
914904926077-02 First registered on 24 Feb 2017
Goals / Remit
Our vision is to be a trusted leader in changing the practice of medicine.
Our mission is to discover new ways to improve and
extend people's lives.
We use science-based innovation to address some of society's most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. We also aim to provide a shareholder return that rewards those who invest their money, time and ideas in our company.Main EU files targeted
ATMP Regulation
Clinical Trials Regulation
Data Protection Regulation
Medical Devices Regulation
In-Vitro Diagnostic Regulation
Orphan Medicinal Products Regulation
Paediatric Regulation
Access to innovation
Antimicrobial resistance (AMR)
Big data
Biosimilars
Innovative Medicines Initiative (IMI)
Industrial policy
EU IP policy
EU research policy
EU trade policy
Health Systems Performance Assessment
Health Technology Assessment & Market Access
Outcomes-based healthcare systems
Patient safety
Pharmaceuticals in the environment
Sustainable Development GoalsAddress
Head Office
Novartis International AG, 1 Forum 1
Basel 4002
SWITZERLANDEU Office
Rue du Trone 108
Brussels 1050
BELGIUM -
People
Total lobbyists declared
13
Employment time Lobbyists 100% 1 75% 1 50% 3 25% 8 Lobbyists (Full time equivalent)
5.25
Lobbyists with EP accreditation
No lobbyists with EP accreditations
Complementary Information
In 2015, eight associates in the Brussels office spent between 25-100% on activities falling within the scope of the register.
Five associates at head quarters spent up to 25% of their time on activities falling within the scope of the register.
All other associates involved on activities falling within the scope of the register spent less than 10% of their time on this.Person in charge of EU relations
Mr von vOlenhusen Max (Head of Brussels Office & EU Relations)
Person with legal responsibility
Mr Jimenez Joe (CEO)
-
Categories
Category
II - In-house lobbyists and trade/business/professional associations
Subcategory
Companies & groups
-
Networking
Affiliation
Among others, Novartis is a member of the following associations: British Chamber of Commerce, EFPIA, Eucomed, EuropaBio, Medicines for Europe.
Member organisations
None declared
-
Financial Data
Closed financial year
Jan 2015 - Dec 2015
Lobbying costs for closed financial year
1,875,000€
Other financial info
All estimates for this submission have been done following the updated Transparancy Register Implementation Guidelines of January 21st, 2015, and are consistent with the guidance provided by the European Federation of Pharmaceutical Industries and Associations (EFPIA).
-
EU Structures
Groups (European Commission)
None
ACC
None
Groups (European Parliament)
None
Communication activities
In January 2015, Novartis organized a lunch debate titled “Eradicating Malaria through Innovation: Where next after 2015?”. One of the objectives was to discuss how to ensure sustainable political commitment for the fight against malaria. Participants included representatives of the EU Institutions (Parliament, Commission), of the WHO, Novartis and others.
Other activities
At European level, Novartis is committed to working in partnership with the institutions of the European Union to support policies and actions that foster positive patient outcomes.
Meetings
Meetings
None declared